SARS-CoV-2 Pseudoviruses

Comprehensive Neutralization Assay Solutions for Advancing SARS-CoV-2 Research

Get your pseudovirus

Our SARS-CoV-2 pseudovirus catalog

Explore our SARS-CoV-2 pseudovirus library. Built on third-generation lentiviral vectors, these pseudoviruses display the glycoprotein of the SARS-CoV-2 virus. If your desired pseudovirus isn’t listed, our custom production service can help. Contact us to learn more

SARS-CoV-2, D614G

SARS-CoV-2, B.1.1.7 (Alpha)

SARS-CoV-2, B1.617.2 (Delta)

SARS-CoV-2, BA.1 (Omicron)

SARS-CoV-2, JN.1

SARS-CoV-2, LP.8.1

KP.3.1.1

Advantages

Our thoroughly validated pseudoviruses come in a range of formats and concentrations, providing the flexibility to fit your experimental setup while ensuring reliable, reproducible results

Sensitive and Easy Detection

Achieve a 10³ RLU signal-to-background ratio with just 1 or 2 µL in a 96-well plate

Support high-throughput screening

Various sizes available: 100 µL, 1 mL, 5 mL, 10 mL or more

Consistent results

Batch-to-batch quality and functional validation (infection, and neutralization)

Flexible reporter system

Luciferase by default, GFP on demand

Order Now

Why SARS-CoV-2 Pseudovirus?

SARS-CoV-2 pseudotyped viral particles offer a powerful, biosafe alternative to live virus for use in neutralization and infectivity assays. Designed to mimic the native structure of SARS-CoV-2, including variant-specific Spike proteins, these non-replicating viral particles are safe to handle in BSL-2 laboratories.

Unlike live viruses, pseudotyped particles deliver consistent antigenic profiles, removing the risk of genetic drift and ensuring experimental reliability. Each particle is engineered to carry a built-in reporter gene, such as luciferase or GFP, allowing for rapid, quantifiable results using standard fluorescence or luminescence-based detection systems.

By eliminating the need for live virus culture, extensive biosafety training, and complex QC procedures, this ready-to-use tool streamlines workflows, reduces turnaround time, and accelerates SARS-CoV-2 research and therapeutic development.

Pseudoviruses for neutralizing antibody (NAbs) detection assays for vaccine development

Applications

Pseudoviruses offer a safe, adaptable platform for influenza research and the advancement of therapeutic strategies. Influenza pseudoviruses serve a wide range of purposes in R&D, including:

Neutralizing Antibody Screening

Vaccine and Antiviral Drug Development

Antiviral Resistance Studies

Fundamental Research on Viral Entry

Long-Term Immunity Across Subpopulations

Order Now

Publications using SARS-CoV-2 pseudoviruses

The pseudovirus neutralization assay, which does not involve infectious viruses and can be performed without a biosafety level 3 laboratory, offers a safe and rapid method for screening neutralizing monoclonal antibodies (mAbs) and antiviral agents targeting the Spike protein of the SARS-CoV-2. During the COVID-19 pandemic, the pseudoviruses assay became one of the methods of reference to accelerate the development of vaccines and anti-viral drugs against SARS-CoV-2.

Get a quote

Documentation

Quality Control Reports

SDS